Compare GRDN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRDN | STOK |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | N/A | 2019 |
| Metric | GRDN | STOK |
|---|---|---|
| Price | $33.54 | $34.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $33.33 | ★ $34.50 |
| AVG Volume (30 Days) | 178.0K | ★ 512.5K |
| Earning Date | 01-01-0001 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | N/A | ★ 0.85 |
| Revenue | N/A | ★ $36,555,000.00 |
| Revenue This Year | $19.50 | $430.19 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $117.77 | ★ $40.40 |
| Revenue Growth | N/A | ★ 316.34 |
| 52 Week Low | $17.78 | $5.35 |
| 52 Week High | $37.43 | $38.62 |
| Indicator | GRDN | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 60.72 |
| Support Level | $31.82 | $30.68 |
| Resistance Level | $33.04 | $34.67 |
| Average True Range (ATR) | 1.43 | 2.27 |
| MACD | -0.07 | 0.27 |
| Stochastic Oscillator | 52.93 | 92.67 |
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.